Wednesday, April 22, 2020 CCTG Planned Trials ALC5 - Novel Therapeutics vs Azacitidine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial) More >> BRC8 - MRI Surveillance with or without Prophylactic Cranial Irradiation in SCLC More >> CEC7 - Post-Surgical (SRS) Compared with (FSRS) for Resected Metastatic Brain Disease More >> CRC9 - Circulating tumOr DNA as a Predictive BiomarRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) More >> HDC1 - Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma More >> OV26 - Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy More >> PR22 - Darolutamide Augments Standard Therapy for Localized High-Risk Prostate Cancer (DASL-HiCaP) More >> Information will be posted shortly on the CCTG website for the following planned trails. GCC1 - Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours HD11 - Pembrolizumab and Brentuximab Vedotin versus GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma PAC3 - Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer
